Carl H. June

California University of Pennsylvania — United States

Medicine · Health Sciences

177h-index143.1kcitations1.4kworks16.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(925), Immune Cell Function and Interaction(346), Immunotherapy and Immune Responses(283), Virus-based gene therapy research(198), T-cell and B-cell Immunology(191)

Publications1.4k total

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia
Blood·2025Open Access
Cytokine receptor armored CAR-T cells enable robust T cell expansion and function in the absence of lymphodepletion
Blood·2025Open Access
557 Evaluation of huCART19-IL18 manufactured using Synecta™ CDNP technology to improve CAR-T yield and consistency in cohort D of an ongoing phase I study (NCT04684563)
Regular and Young Investigator Award Abstracts·2025Open Access
275 All-in-one CAR T cell platform for safe and effective targeting of metastatic castration-resistant prostate cancer
Regular and Young Investigator Award Abstracts·2025Open Access
Ping-pong dual CAR T cells: antigen-specific peripheral expansion of dual-targeted CAR T cells boosts antitumor immunity against solid tumors 2126
The Journal of Immunology·2025Open Access
IL-9 signaling enhances CAR T cell antitumor efficacy in solid tumors by promoting memory phenotypes and reducing dysfunction under antigen stress 2144
The Journal of Immunology·2025Open Access
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy
Nature Biomedical Engineering·2025· 1 cited
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy
Nature reviews. Immunology·2025· 4 cited
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery
Nature Biomedical Engineering·2025· 12 citedOpen Access
In vivo chimeric antigen receptor (CAR)-T cell therapy
Nature Reviews Drug Discovery·2025· 16 cited
From bench to bloodstream: Lipid nanoparticles drive on-demand CAR-T cells
Molecular Therapy·2025Open Access
Multiplex engineering using microRNA-mediated gene silencing in CAR T cells
Frontiers in Immunology·2025· 2 citedOpen Access
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer
Cell Reports Medicine·2025· 2 citedOpen Access
The senescence-inhibitory p53 isoform Δ133p53α: enhancing cancer immunotherapy and exploring novel therapeutic approaches for senescence-associated diseases
GeroScience·2025· 2 citedOpen Access
Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic Cancer
2025Open Access
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy
Journal for ImmunoTherapy of Cancer·2025Open Access
Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM
Frontiers in Immunology·2025· 1 citedOpen Access
In vivo CAR T cell generation to treat cancer and autoimmune disease
Science·2025· 122 cited
DR5 CAR-T cells target solid tumors and suppress MDSCs with minimal toxicity
2025Open Access
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
Nature Medicine·2025· 3 citedOpen Access
← Previouspage 2 of 71Next →

Frequent Co-authors

Bruce L. Levine(25), Simon F. Lacey(14), J. Joseph Melenhorst(13), Michael Kalos(11), Stephan A. Grupp(9), David L. Porter(8), James L. Riley(8), Michael C. Milone(7), Gabriela Plesa(7), Marcela V. Maus(7), Wei‐Ting Hwang(7), Joseph A. Fraietta(7), Irina Kulikovskaya(7), Anne Chew(6), Minnal Gupta(6), Regina M. Young(6), Edward A. Stadtmauer(6), Yangbing Zhao(6), Noelle V. Frey(5), Zhaohui Zheng(5)